TY - JOUR
T1 - Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
AU - Viúdez, Antonio
AU - Crespo, Guillermo
AU - Gómez Dorronsoro, María Luisa
AU - Arozarena, Imanol
AU - Marín-Méndez, Juan Jesús
AU - Custodio, Ana
AU - Benavent, Marta
AU - Goñi, Saioa
AU - García-Paredes, Beatriz
AU - Hernando, Jorge
AU - Durantez, Maika
AU - Alonso, Vicente
AU - Riesco, María del Carmen
AU - López, Carlos
AU - Jiménez-Fonseca, Paula
AU - San Vicente, Borja López
AU - González-Borja, Iranzu
AU - Sevilla, Isabel
AU - Hernández-Garcia, Irene
AU - Carmona-Bayonas, Alberto
AU - Capdevila, Jaume
AU - Pérez-Sanz, Jairo
AU - García-Carbonero, Rocío
AU - Pérez-Ricarte, Leyre
AU - Llanos, Marta
AU - Vera, Ruth
AU - De Jesús Acosta, Ana
N1 - Publisher Copyright:
© 2020 IAP and EPC
PY - 2021/1
Y1 - 2021/1
N2 - Background: Pancreatic neuroendocrine tumors are rare neoplasms for which few predictive and/or prognostic biomarkers have been validated. Our previous work suggested the potential of the combined expression of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) as prognostic factors for relapse and survival. Methods: In this new multicenter study we evaluated immunohistochemistry expression in 76 patients with advanced PanNET who were treated with capecitabine-temozolomide or everolimus. Based on the immunohistochemistry panel, an immunohistochemistry prognostic score (IPS) was developed. Results: In patients treated with capecitabine and temozolomide, low IPS was an independent prognostic factor for progression-free-survival and overall-survival. Similar findings were observed with highest IPS for overall-survival in patients treated with everolimus. Conclusion: From our knowledge, it is the first time that a simple IPS could be useful to predict outcome for patients with metastatic pancreatic neuroendocrine tumors treated with everolimus or capecitabine and temozolomide.
AB - Background: Pancreatic neuroendocrine tumors are rare neoplasms for which few predictive and/or prognostic biomarkers have been validated. Our previous work suggested the potential of the combined expression of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) as prognostic factors for relapse and survival. Methods: In this new multicenter study we evaluated immunohistochemistry expression in 76 patients with advanced PanNET who were treated with capecitabine-temozolomide or everolimus. Based on the immunohistochemistry panel, an immunohistochemistry prognostic score (IPS) was developed. Results: In patients treated with capecitabine and temozolomide, low IPS was an independent prognostic factor for progression-free-survival and overall-survival. Similar findings were observed with highest IPS for overall-survival in patients treated with everolimus. Conclusion: From our knowledge, it is the first time that a simple IPS could be useful to predict outcome for patients with metastatic pancreatic neuroendocrine tumors treated with everolimus or capecitabine and temozolomide.
KW - Biomarker
KW - Immunohistochemistry
KW - MGMT
KW - Metastatic pancreatic neuroendocrine tumor
KW - NDRG-1
KW - PHLDA-3
KW - Predictive factor
KW - Prognosis factor
UR - http://www.scopus.com/inward/record.url?scp=85098104660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098104660&partnerID=8YFLogxK
U2 - 10.1016/j.pan.2020.12.009
DO - 10.1016/j.pan.2020.12.009
M3 - Article
C2 - 33358592
AN - SCOPUS:85098104660
SN - 1424-3903
VL - 21
SP - 215
EP - 223
JO - Pancreatology
JF - Pancreatology
IS - 1
ER -